Congress to Clinic: Post-ELCC Updates on Antibody–Drug Conjugates in NSCLC

In this episode,Egbert F. Smit, MD, PhD; David Planchard, MD, PhD; and  Helena A. Yu, MD, answer audience questions from a live webinar regarding clinical data on antibody–drug conjugates in NSCLC including:Biopsies and biomarker testing considerationsTumor heterogeneity and targeting of brain metastasesLiquid biopsiesSequencing of ADCs following previous therapyToxicity managementPresenters:Egbert F. Smit, MD, PhDProfessorDepartment of Pulmonary DiseasesLeiden University Medical CenterLeiden, NetherlandsDepartment of Thoracic OncologyNetherlands Cancer InstituteAmsterdam, NetherlandsDavid Planchard, MD, PhDHead of Thoracic GroupDepartment of Medical OncologyInstitute Gustave RoussyVillejuif, FranceHelena A. Yu, MDAssistant AttendingDepartment of MedicineMemorial Sloan Kettering Cancer CenterNew York, New YorkContent based on an online CME program supported by an educational grant from Daiichi Sankyo, Inc.Congress to Clinic: Post-ELCC Updates on Antibody–Drug Conjugates in NSCLC - Oncology - Clinical Care Options (clinicaloptions.com)Link to full program:https://bit.ly/3fr2G6G

There are no comments yet.

Please log in to write the first comment.